Promising early-phase clinical trial results for several first-in-class therapeutics with innovative mechanisms of action and cutting-edge technologies were recently presented at #Targets25. Learn more on the #AACRBlog: buff.ly/hNZxH9V
Zenocutuzumab-zbco led to responses in 37% of patients in a small cohort of patients with NRG1+ cholangiocarcinoma
🔹Clinical benefit rate 58%, median PFS of 9.2 months
🔹Presented at #Targets25 by Alison Schram, MD of @mskcancercenter.bsky.social
ascopost.com/news/october...
An investigational inhibitor of active KRAS G12C showed promise for patients with metastatic NSCLC, including for those whose tumors had features consistent with resistance to other KRAS G12C inhibitors, according to clinical trial results reported at #Targets25. buff.ly/7ZvDYDK
The HER2/HER3-targeted bispecific antibody zenocutuzumab was associated with a 37% overall response rate in patients with a rare cholangiocarcinoma enrolled in the eNRGy phase II clinical trial, as reported at #Targets25. buff.ly/2ef2d6n
Cancer Research Executive Editor Harmony Turk, PhD, will be at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or are interested in discussing your research, reach out to her at harmony.turk@aacr.org. #Targets25
Here are the 4 abstracts exploring novel therapeutics for patients with marginal zone lymphomas we're presenting at the #Targets25:
-Epigenetic vulnerabilities in marginal zone lymphoma
doi.org/10.1158/1535...
@iorbellinzona.bsky.social @usi.ch
An investigational DLL3-targeting antibody-drug conjugate, ZL-1310, showed safety and anticancer responses in patients with extensive-stage small cell lung cancer. Grace K. Dy, MD, of @roswellpark.bsky.social presented phase I clinical trial results at #Targets25. buff.ly/iZCWaXU
Ines Pulido presents her poster at #Targets25 and is pictured here with corresponding author Takeshi Shimamura and Associate Editor Danielle Large.
Read the article published simultaneously: Heterobifunctional KRASG12D-HSP90 Inhibitors buff.ly/XRF1cAw
Attending #Targets25? Read this collection of articles that features recent research and review articles highlighting key advances in PROTAC and molecular glue development buff.ly/xdWDulw
In a phase I clinical trial, the first-in-class PPARG inhibitor FX-909 showed early clinical activity in treating patients with advanced urothelial carcinoma, based on phase I trial results presented by Xin Gao, MD, at #Targets25.
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
Cancer Discovery Senior Executive Editor Robert Kruger, PhD, will be at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or want to discuss your research, please reach out to him at robert.kruger@aacr.org. #Targets25
Cancer Research Communications Associate Editor Emily Frieben, PhD, will be at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or want to discuss your research, reach out to her at emily.frieben@aacr.org. #Targets25
Curious about opportunities to publish in AACR Journals? Visit AACR booth #101 at #Targets25 on October 24 at 1PM to chat with in-house editors Emily Frieben, PhD, and Danielle Large, PhD, about your research and publishing opportunities.
📢We’re ready— #Targets25 kicked off!
www.aacr.org/meeting/aacr...
Our lab will share new work on epigenetic targets in leukemia 🧬🎯.
Join us Sat, Oct 25 in Plenary Session 6 where invited speaker Irmela Jeremias highlights how PDX models reveal actionable targets.
#Leukemia #Epigenetics
Molecular Cancer Therapeutics Associate Editor Danielle Large, PhD, will be at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or want to discuss your research, reach out to her at danielle.large@aacr.org. #Targets25
Are you attending #Targets25? Visit the @theaacr.bsky.social booth to learn more about AACR Project GENIE and cBioPortal. cBioPortal team members will be present to help answer your questions.
See you soon! #Targets25
Foundation Medicine will be at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025
Research Highlight at #Targets25 - Clinical value of ctDNA tumor fraction (TF) and evolving genomic landscape across lines of therapy (LOTs) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Research Highlights at #Targets25 - Clinical Value of Tumor Mutational Burden (TMB) for Neoadjuvant and Adjuvant Immune Checkpoint Inhibitor (ICI) in Early-Stage (I-III) Non-Small Cell Lung Cancer (NSCLC)
Research Highlights at #Targets25 - Natural history and prognostic value of TP53 Y220C mutation in advanced solid tumors: A real-world study
Our team is excited to attend #Targets25 in Boston next week! Visit booth 216 to learn more about Foundation Medicine’s high-quality portfolio of precision diagnostic solutions. Scroll through for more about our research being presented. Connect with us: spkl.io/63328AnIH4
Pheast will present a trial-in-progress poster at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 22–26 in Boston.
For more on #Targets25, visit: www.aacr.org/meeting/aacr...
Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy
Merus’ plenary session oral presentation on petosemtamab in metastatic colorectal cancer will be on October 24, 10:00 -11:40 a.m. ET at #Targets25.
The poster on the preclinical evaluation of petosemtamab on cancer stem cells will be on October 24, 12:30-4:00 p.m. ET.
ir.merus.nl/news-release...
Are you attending the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston? Reach out to Cancer Cell editor @montse-rojo.bsky.social to discuss your work #Targets25 @theaacr.bsky.social
Register by September 22 to get the lowest rates for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more:
buff.ly/0ZizQBA
#Targets25
Register by September 22 to get the lowest rates for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more:
buff.ly/0ZizQBA
#Targets25
#ScientificAgenda
#Targets25 Oct. 22-26, Boston
Register by September 22 to get the lowest rates for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 22-26; Boston), chaired by Ryan B. Corcoran, Tim F. Greten, and Elena Garralda. Learn more:
buff.ly/0ZizQBA
#Targets25
